Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly announced positive topline results from the Phase 3b TOGETHER-PsO trial, which ...
February 19-22 event in Sarasota, Florida features hands-on ultrasound training and sessions on emerging biologics, ...
Everyday Health on MSN
A drug combo that includes a GLP-1 may improve psoriasis and psoriatic arthritis symptoms
The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.
"Understanding biologic therapy trajectories in Medicaid is important, given its distinct formulary restrictions and patient demographics," they concluded. "Interventions must not only address access ...
Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and ...
New findings indicate that in adults with moderate-to-severe plaque psoriasis who are overweight or obese, combined treatment with ixekizumab (Taltz) and tirzepatide (Zepbound) results ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b ...
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...
The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV ...
From reducing lesions to truly improving quality of life. Today, the management of psoriasis and atopic dermatitis is ...
Identification of sub-categories of the disease linked to gene expression also sheds light on why current treatments may fail. A man scratching with ...
Patients with psoriasis were associated with significantly lower circulating BDNF levels compared with healthy control individuals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results